{{Rsnum
|rsid=12190776
|Gene=NKAIN2
|Chromosome=6
|position=123981398
|Orientation=plus
|GMAF=0.2236
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=NKAIN2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 54.0 | 33.6 | 12.4
| HCB | 68.6 | 27.0 | 4.4
| JPT | 69.0 | 28.3 | 2.7
| YRI | 73.5 | 19.7 | 6.8
| ASW | 64.3 | 30.4 | 5.4
| CHB | 68.6 | 27.0 | 4.4
| CHD | 74.3 | 23.9 | 1.8
| GIH | 73.3 | 22.8 | 4.0
| LWK | 75.5 | 23.6 | 0.9
| MEX | 58.6 | 37.9 | 3.4
| MKK | 78.2 | 20.5 | 1.3
| TSI | 53.9 | 41.2 | 4.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12190776
|Name_s=
|Gene_s=NKAIN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. In combination, rs278917, rs10061997, rs12190776, and rs9730073 were all significant predictors of etoposide IC50, and accounted for 40% of the etoposide IC50 variation in Yorubans.Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00001. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109523
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12190776
|overall_frequency_n=30
|overall_frequency_d=128
|overall_frequency=0.234375
|n_genomes=23
|n_genomes_annotated=0
|n_haplomes=24
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}